Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer disease psychosis: A post hoc analysis

In this 12‐week, randomized, double‐blind, placebo‐controlled study (ACP‐103‐019), researchers evaluated if treatment with pimavanserin reduced Alzheimer disease psychosis (ADP) and associated agitation and aggression. They tested the efficacy of reducing psychotic symptoms in patients with ADP of pimavanserin 34 mg. According to this post hoc responder analysis, improvements in psychotic symptoms in patients receiving pimavanserin were correlated with an improvement in agitation and aggression symptoms. Patients showing ≥ 50% improvement in psychotic symptoms from baseline to week 6 of treatment with pimavanserin reported greater improvement in agitation and symptoms of aggression vs nonresponders.